Abivax (ABVX) Change in Receivables (2024 - 2026)

Abivax's Change in Receivables history runs 3 years deep, the most recent figure standing at -$4.1 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 79.44% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was $6.5 million, a 95.03% increase from a year earlier, with the FY2025 full-year figure at $8.2 million, up 64.97% from the prior year.
• Change in Receivables eased to -$4.1 million in Q1 2026 per ABVX's latest filing, from $10.9 million in the prior quarter.
• Across five years, Change in Receivables topped out at $10.9 million in Q4 2025 and bottomed at -$5.4 million in Q3 2025.
• The 3-year median for Change in Receivables is -$735466.9 (2024), against an average of $1.0 million.
• Biggest YoY gain for Change in Receivables was 215.48% in 2025; the steepest drop was 209.07% in 2025.
• Year by year, Change in Receivables stood at $3.4 million in 2024, then soared by 215.48% to $10.9 million in 2025, then tumbled by 137.5% to -$4.1 million in 2026.
• Per Business Quant, the three latest ABVX Change in Receivables figures stand at -$4.1 million (Q1 2026), $10.9 million (Q4 2025), and -$5.4 million (Q3 2025).